Beta Bionics preliminary Q4 net sales rise

Beta Bionics

08/01/2026 21:22

Overview

Diabetes management firm's preliminary Q4 net sales rose, beating analyst expectations

DME channel net sales expected to rise 23% yr/yr in the quarter

PBP channel net sales expected to rise yr/yr

Outlook

Company did not provide specific guidance for future quarters or full year 2026

Result Drivers

PBP CHANNEL GROWTH - PBP channel net sales expected to rise yr/yr, driven by increased reimbursement through this channel

INSTALLED BASE EXPANSION - Installed customer base expected to grow yr/yr, reflecting strong adoption of iLet Bionic Pancreas

NEW PATIENT STARTS - New patient starts expected to increase 36% yr/yr, with 69% coming from multiple daily injections

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net sales
Beat
$32 mln
$28.90 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Beta Bionics Inc is $32.50, about 3.2% above its January 7 closing price of $31.49

Press Release: ID:nGNX9Dyf1M

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)